Multi-Cancer Early Detection in the Primary Care Setting
Released On
October 17, 2022
Expires On
October 17, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology, Neonatology
Topic(s)
Bone Cancer, Brain Cancer, Breast Cancer, Colon Cancer, Gastric Cancer, Lung Cancer, Oncology, Prostate Cancer
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Purdue University College of Pharmacy.
This activity is supported by an independent educational grant from Grail.
Credit Available
- Physicians — maximum of 1.75 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
The target audience for this curriculum are primary care physicians, internal medicine, and related health care professionals involved in screening patients for cancer. Health-care professionals may be unfamiliar with the concept of patient-centered care models that provide optimal outcomes for screening patients for cancer.
Program Overview
This two part curriculum covers the following topics:
Module 1: Cancer screening: Now and in the Future
This module will discuss the current recommendations for cancer screening and potential role of cell free DNA technologies in early cancer detection strategies. It will also discuss the advantages of multi-cancer early detection screening testing compared to current screening tests.
Module 2: MCED: Economics, Applications in Primary Care Settings, Workflow Integration, and Benefits to Individualized Treatment
This module will discuss the impact and value of traditional cancer screening as compared to MCED testing as well as outline the role of the primary care clinician in MCED testing. There will also be discussion on how to implement MCED testing into current office workflows and further discussion on the current and future role of MCED testing in the management of selected cancers.
Learning Objectives
Learning Objectives for Module #1
- Describe current recommendations for cancer screening and early detection.
- Explain how DNA methylation from circulating cell-free DNA samples in combination with liquid biopsy identify circulating epigenetic biomarkers of clinical importance to enable early detection.
- Evaluate the comparative advantages of multi-cancer screening testing as a complement to imaging and biopsy-based, single-cancer screening methods in reducing cancer morbidity and mortality through earlier detection.
Learning Objectives for Module #2
- Analyze the impact and value of traditional cancer screening, emerging diagnostics, and MCED testing for cancer.
- Illustrate the role of the managed care professional in integrating multi-cancer screening testing into patient care and workflow in the primary care setting.
- Assess the role of liquid biopsy testing to help inform individualize treatment protocols and follow up for cancer patients.
Faculty
Charles Vega, MD (Chairperson)
Clinical Professor, Family Medicine
Director,
UC Irvine Program in Medical Education for the Latino Community (PRIME-LC), Family
Medicine
Associate Dean,
School of Medicine
University of California, Irvine
Orange, California
Chuck grew up in Northern California and completed his undergraduate degree at Harvard University. He attended medical school at the University of Wisconsin - Madison and completed residency training in family medicine at UC Irvine. He stayed on as faculty in the Department of Family Medicine at UCI and now holds the title of health sciences clinical professor. He is the executive director of UCI’s Program in Medical Education for the Latino Community and won a Macy Faculty Scholarship to improve patient-centered health education at UCI. He assumed the role of associate dean for Diversity and Inclusion at the UCI School of Medicine in July, 2016. Dr. Vega has seen patients and taught medical students and residents at UC Irvine’s Family Health Center – Santa Ana for the past 20 years. This clinic is a federally-qualified health center and the largest safety-net clinic for Orange County. Dr. Vega’s academic interests are focused on access to quality, compassionate medical care for underserved populations and the development of training programs to promote this vision of health care.
Eric Klein, MD
Chair of the Glickman Urological and Kidney Institute
Professor of Surgery
Lerner College of Medicine of the Cleveland Clinic
Cleveland, OH
Eric Klein, MD is the Andrew C. Novick Distinguished Chair of the Glickman Urological and Kidney Institute and Professor of Surgery in the Lerner College of Medicine of the Cleveland Clinic. He joined the staff of the Cleveland Clinic in 1989. His career has been focused on clinical, translational, and basic science aspects of prostate cancer.Eric is a member of numerous professional societies and scientific advisory boards including the Board of Scientific Counselors – Clinical Sciences and Epidemiology of the National Cancer Institute, the American Association of Genitourinary Surgeons, the Clinical Society of Genitourinary Surgeons, and the Society of Urologic Oncology. He has contributed more than 600 papers to the scientific literature and authored or edited eight books on urologic malignancies, and his contributions to the field have been recognized by five Career Achievement Awards including a 2014 Presidential Citation from the American Urological Association, the 2014 Huggins Medal from the Society of Urologic Oncology, the 2015 Philip S. Hench Award from the University of Pittsburgh School of Medicine, the 2020 SUO Medal from the Society of Urologic Oncology, and the 2020 Richard D. Williams, MD Prostate Cancer Research Excellence Award.
Tom Beer, M.D.
Tomasz M. (Tom) Beer holds the Grover C. Bagby Endowed Chair for Prostate Cancer Research and serves as Professor of Medicine, Deputy Director at the Oregon Health & Science University Knight Cancer Institute and Chief Medical Officer of the Center for Early Detection Advanced Research (CEDAR) in Portland, Oregon. Dr. Beer leads the Prostate Cancer Research Program within the OHSU Knight Cancer Institute, an NCI-designated Comprehensive Cancer Center.
He received his medical degree from Johns Hopkins School of Medicine, Baltimore, Maryland, in 1991. He then moved to Oregon Health & Science University. At OHSU he completed his internship and residency in internal medicine and a fellowship in Hematology and Medical Oncology.
As Deputy Director, Dr. Beer contributed to the Knight Cancer Institute achieving Comprehensive Status in 2017 on the heels of a successful $1B philanthropic campaign anchored by a historic $500M challenge gift from Phil and Penny Knight. He has provided oversight to the Cancer Institute’s clinical enterprise, administration, operations, strategic planning, regional partnerships, and clinical research programs, served on institutional leadership committees and represented the institute internally as well with external partners, media, and the public.
As CEDAR Chief Medical Officer, he represents clinicians and patients and provides medical leadership to the OHSU Knight Cancer Institute’s premiere new initiative, a $500M, 10-year program to advance the early detection of lethal cancer.
Dr. Tomasz Beer has authored and co-authored more than 350 articles and abstracts on prostate cancer largely with a focus on the development of novel therapies through clinical and translational investigation. He co-authored the book Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials. Dr. Beer is particularly known for investigations of targeted therapies and immunotherapies in prostate cancer, including vitamin D receptor, the androgen receptor, and clusterin targeting agents as well as cancer vaccines, CTLA-4 and PD-1 inhibitors, and others. He led the global randomized trial of enzalutamide vs placebo which demonstrated substantial improvements in overall and progression-free survival as well as quality of life and served as the basis for a global change in the standard of care for advanced prostate cancer. At CEDAR, Dr. Beer fosters collaborations between clinicians, engineers, and cancer biologists to advance discoveries in early detection of cancer and leads clinical trials of multi-omic blood based cancer early detection tests. Dr. Beer cares for men with prostate cancer at OHSU and at the Portland VA Medical Center.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Simumetrix. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Purdue University College of Pharmacy designates this internet enduring activity for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Association of Nurse Practitioners (NPs) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Additionally, the American Academy of Physician Assistants (PAs) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. For the purpose of recertification, the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME. As a result, nurses, physician assistants and nurse practitioners will be included in the target audience for this program.
Disclosures of Conflicts of Interest
To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.
- Charles Vega, MD
-
- Consultant: Johnson and Johnson, GlaxoSmithKline
- Tom Beer, MD
-
- Research Funding Paid: Institution Alliance Foundation Trials, Astellas Pharma, Bayer, Boehringer Ingel
- Consultant: AbbVie, Amgen, Arvinas, Astellas Pharma, AstraZeneca, Bayer, Brito
- Stock Ownership : Arvinas Inc, Salaruis Pharmaceuticals
- Eric Klein, MD
-
- Consultant: Grail, Inc.
All relevant conflicts of interest have been mitigated prior to the start of the activity.
None of the planners, reviewers, Simumetrix staff and ArcheMedX Staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be available to the participant to claim after completing both modules, passing the post-tests and submitting the evaluation.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Purdue University requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: pharmacy-cecr@purdue.edu.